Skip to main content
Terug
Watch Compare

Tempest Therapeutics, Inc.

Datakwaliteit: 83%
TPST
Nasdaq Manufacturing Chemicals
€ 1,56
€ 0,00 (0,00%)
Marktkapitalisatie: 22,38 M
Prijs
€ 1,56
Marktkapitalisatie
22,38 M
Dagbereik
€ 1,55 — € 1,63
52-Weeksbereik
€ 1,50 — € 12,23
Volume
104.419
Openen € 1,56
50D / 200D Gem.
€ 2,26
31,00% below
50D / 200D Gem.
€ 6,08
74,34% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -26,82 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-325,65%
Onder sectorgemiddelde (-53,47%)
ROIC-135,68%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio2,30
Interest Coverage-128,38

Waardering

PE (TTM)
-0,85
Boven sectorgemiddelde (-1,47)
P/B Ratio3,53
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,9 -1,5
P/B 3,5 1,6
ROE % -325,7 -53,5
Net Margin % -41,5
Rev Growth 5Y % 1,8
D/E 0,3

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -26,26 M
ROE -325,65% ROA -126,22%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -26,82 M
ROIC -135,68% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2,30
Interest Coverage -128,38 Asset Turnover N/A
Working Capital 4,58 M Tangible Book Value 6,35 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,85 Forward P/E N/A
P/B Ratio 3,53 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -119,86%
Market Cap 22,38 M Enterprise Value 14,86 M
Per Share
EPS (Diluted TTM) -6,33 Revenue / Share N/A
FCF / Share -1,87 OCF / Share -1,87
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 102,12%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue
Net Income -26,26 M -41,84 M -29,49 M -35,71 M -28,30 M
EPS (Diluted) -6,33 -1,50 -1,91 -3,09 -7,47
Gross Profit
Operating Income -26,58 M -42,03 M -29,16 M -34,64 M -26,99 M
EBITDA
R&D Expenses
SG&A Expenses
D&A
Interest Expense 207.000,0 1,32 M 1,45 M 1,62 M 1,28 M
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 16,93 M 41,49 M 51,60 M 46,09 M 73,24 M
Total Liabilities 10,26 M 22,36 M 24,84 M 27,98 M 37,12 M
Shareholders' Equity 6,67 M 19,13 M 26,77 M 18,11 M 36,12 M
Total Debt 6,40 M 10,50 M 10,40 M 15,07 M
Cash & Equivalents 7,71 M 30,27 M 39,23 M 31,23 M 51,83 M
Current Assets 8,27 M 31,47 M 40,36 M 32,95 M 68,96 M
Current Liabilities 3,31 M 14,22 M 9,41 M 7,28 M 20,03 M